Alcon Inc. (ALC)
| Market Cap | 39.15B |
| Revenue (ttm) | 10.19B |
| Net Income (ttm) | 1.05B |
| Shares Out | 491.20M |
| EPS (ttm) | 2.10 |
| PE Ratio | 37.39 |
| Forward PE | 23.97 |
| Dividend | $0.22 (0.27%) |
| Ex-Dividend Date | May 14, 2025 |
| Volume | 1,480,172 |
| Open | 80.20 |
| Previous Close | 79.67 |
| Day's Range | 78.96 - 80.20 |
| 52-Week Range | 71.55 - 99.20 |
| Beta | 0.69 |
| Analysts | Buy |
| Price Target | 88.29 (+11.76%) |
| Earnings Date | Feb 24, 2026 |
About ALC
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. It operates through two segments, Surgical and Vision Care. The company offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, Verion reference unit and Verion digital marker, ... [Read more]
Financial Performance
In 2024, Alcon's revenue was $9.91 billion, an increase of 4.82% compared to the previous year's $9.46 billion. Earnings were $1.02 billion, an increase of 4.52%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for ALC stock is "Buy." The 12-month stock price target is $88.29, which is an increase of 11.76% from the latest price.
News
Alcon Inc. (ALC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Alcon Inc. (ALC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Alcon Terminates Agreement to Acquire STAAR Surgical
GENEVA--(BUSINESS WIRE)--Alcon Terminates Agreement to Acquire STAAR Surgical.
STAAR Surgical Merger With Alcon Fails After Shareholders Vote No
STAAR Surgical Company (NASDAQ: STAA) announced Tuesday that it did not receive the necessary stockholder votes to approve the merger agreement with Alcon Inc. (NYSE: ALC) at the Special Meeting of St...
Broadwood Partners Comments on STAAR Surgical Shareholders' Rejection of the Company's Proposed Sale to Alcon
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”), which together own 30.2% of the outstanding common stock of STAAR Surgical Company (“STAAR” or the “Compan...
Staar Surgical to reject Alcon takeover bid after failing to win shareholder backing
STAAR Surgical said on Tuesday it plans to terminate its merger agreement with Swiss eyecare giant Alcon after failing to secure enough shareholder votes to approve the deal, sending its shares down m...
Alcon to Present at 2026 Annual J.P. Morgan Healthcare Conference
GENEVA--(BUSINESS WIRE)--Regulatory News: Alcon (SIX/NYSE: ALC) CEO David Endicott will present at the 2026 J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 a.m. PST. A live web...
Broadwood Partners Denounces STAAR Surgical's Fourth Delay of the Shareholder Vote on the Company's Proposed Sale to Alcon
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”), which together own 30.2% of the outstanding common stock of STAAR Surgical Company (“STAAR” or the “Compan...
Alcon Exercises Right to Require STAAR Surgical to Adjourn its Special Meeting of Stockholders
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the manufacturer of the Implantable Collamer® Lens (ICL) today announced that Alcon (SIX/NYSE: ALC) has exercised its right...
Defender Capital Reiterates Intention to Vote AGAINST STAAR Surgical's Proposed Sale to Alcon Inc.
Expresses Disappointment in the Board's and Management's Continued Pursuit of Ill-advised Deal CHARLOTTE, N.C. , Dec. 17, 2025 /PRNewswire/ -- Defender Capital ("Defender" or "we"), a long-term shareh...
Broadwood Partners Issues Open Letter to STAAR Surgical Board Pledging Cooperation and Support When Vote on Alcon Transaction Fails
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today issued the following letter to the Board of Directors (the “Board”) of STAAR Surgical Company (...
STAAR Stockholders Have a Choice: Vote FOR Alcon's Certain, Premium $30.75 Per Share Cash Offer or Bear the Downside Risk that Broadwood Has No Credible Plan to Create Stockholder Value
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, toda...
Independent Industry Analysts Recognize Value Provided to STAAR Stockholders by Amended Alcon Merger Agreement and Merits of Alcon Transaction
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, toda...
Broadwood Partners Comments on ISS Report on Proposed Sale of STAAR Surgical to Alcon
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today commented on a report published by Institutional Shareholder Services Inc. (“ISS”), an independent pr...
Broadwood Partners: Leading Proxy Advisory Firm Glass Lewis Reaffirms Recommendation “AGAINST” STAAR Surgical Sale to Alcon
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today announced that Glass, Lewis & Co., LLC (“Glass Lewis”), a leading independent proxy advisory firm, ha...
STAAR Surgical Sets the Record Straight Regarding its Robust Go-Shop Process
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, toda...
Broadwood Partners Comments on STAAR Surgical Board Dissent on the Revised Sale to Alcon
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood,” “we,” “us” or “our”) today reacted to the proxy statement supplement filed by STAAR Surgical Company ...
STAAR Surgical's Top Investors Reject Sweetened Alcon Offer, Cite Flawed Sale Process
Yunqi Capital Limited, which holds a 5.1% stake in STAAR Surgical Company (NASDAQ: STAA), issued a letter to shareholders on Wednesday.
Yunqi Capital Comments on STAAR Surgical's Go-Shop Process and Alcon's Revised Offer
HONG KONG--(BUSINESS WIRE)--Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company...
Broadwood Partners Responds to Alcon's Increase to Proposed Acquisition Price of STAAR Surgical
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood,” “we,” “us” or “our”) today responded to the amended transaction terms of the proposed acquisition of ...
Alcon lifts bid for medical technology firm Staar to $1.6 billion
Swiss eyecare giant Alcon has lifted its bid to acquire Staar Surgical to $30.75 per share in cash, it said on Tuesday, valuing the medical technology firm at $1.6 billion.
Alcon Announces Amended Merger Agreement with STAAR Surgical
GENEVA--(BUSINESS WIRE)--Alcon Announces Amended Merger Agreement with STAAR Surgical.
Broadwood Partners Reiterates Opposition to STAAR Surgical's Sale to Alcon Following Conclusion of Performative Go-Shop Process
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood,” “we,” “us,” or “our”) today issued the following open letter to the shareholders of STAAR Surgical Co...
Broadwood Partners: Proxy Advisory Firm Egan-Jones Reaffirms Its Recommendation STAAR Surgical Shareholders Vote “AGAINST” Sale to Alcon
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today announced that leading proxy advisory firm Egan-Jones Ratings Company (“Egan-Jones”) has reaffi...
STAAR Surgical Announces Expiration of Go-Shop Period
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, toda...
Alcon: Some Premium Coming Out Of This Quality Play
Alcon Inc. remains a global leader in eye care, benefiting from aging demographics and technological innovation, but faces valuation and growth headwinds. Recent M&A activity, including the pending ST...